Research
Hormonal
Exposure to environmental endocrine-disrupting chemicals (EDCs) is associated with adverse neurodevelopmental outcomes in children, including lower IQ, attention deficit, hyperactivity, and behavioral problems.
Reduce exposure to EDCs during pregnancy and childhood by avoiding plastic food storage, choosing natural personal care products, and filtering drinking water to protect developing brains.
ModerateSupportsMEDIUM confidence
In utero exposure to phthalates is shown to be associated with adverse cognitive and behavioral outcomes such as lower IQ, attention deficit, hyperactivity and poorer social communication in children... Other EDCs such as organophosphates, PBDEs, perfluorinated compounds, and PCBs have also been linked to adverse neurodevelopmental performance, behavioral problems and lower IQ to varying degrees.
Why this rating
The paper cites multiple studies linking EDCs to neurodevelopmental issues, but notes that results can be variable and sex-specific.
Source
Environmental Endocrine-Disrupting Chemical Exposure: Role in Non-Communicable Diseases
Manoj Kumar et al. · Frontiers in Public Health · 2020
DOI 10.3389/fpubh.2020.553850
narrative_reviewCited 374×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exposure to environmental endocrine-disrupting chemicals (EDCs) such as BPA, phthalates, and persistent organic pollutants acts as an obesogen, contributing to obesity, metabolic syndrome, and type 2 diabetes by disrupting endocrine pathways, adipogenesis, and gut microbiota.Moderate
- Exposure to environmental endocrine-disrupting chemicals (EDCs) is associated with adverse reproductive health outcomes in both males and females, including reduced fertility, altered puberty timing, and increased risk of conditions like PCOS and endometriosis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →